Business
Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026
Allschwil, Switzerland – May 6, 2026At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors. The meeting was attended by 213 shareholders, representing a total of 107’812’120 shares, or 43% of the total outstanding shares. Jean-Paul Clozel, MD, Chairman of the Board of Directors and interim CEO of Idorsia, commented:“On behalf of the Board, I would like to thank our sharehol
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hFCnMmy9Ihh7UbzaqwJr7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/hFCnMmy9Ihh7UbzaqwJr7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"text","content":"Allschwil, Switzerland – May 6, 2026At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors.","length":216,"tagName":"p"},{"type":"text","content":"The meeting was attended by 213 shareholders, representing a total of 107’812’120 shares, or 43% of the total outstanding shares.","length":129,"tagName":"p"},{"type":"text","content":"Jean-Paul Clozel, MD, Chairman of the Board of Directors and interim CEO of Idorsia, commented:“On behalf of the Board, I would like to thank our shareholders for their continued trust and support. Idorsia is a commercial‑stage biotech with a strong foundation. We have two products with blockbuster potential, an innovative pipeline of first or best-in-class medicines, and a near-term path to financial independence. With the election of Natalia Misciattelli, Gabriel Baertschi, and André Muller, the Board is fully aligned to support the next phase of growth, alongside progressing the search for the right CEO who shares our vision. Our clear focus is on accelerating QUVIVIQ sales, advancing our pipeline, and creating sustainable long‑term value.”","length":754,"tagName":"p"},{"type":"text","content":"The shareholders approved the Annual Report 2025, the Consolidated Financial Statements 2025, and the Statutory Financial Statements 2025. Shareholders also endorsed the Compensation Report 2025 and the Sustainability Report 2025 by way of consultative vote.","length":258,"tagName":"p"},{"type":"text","content":"The shareholders approved th...